The FDA recently approved gene therapies used to treat hemophilia A and B. This Sun Life Bright Paper dives deeper into Roctavian and Hemgenix, other treatments, their costs, and more. This is a big step forward in hemophilia care!
Breast cancer is one of the most common cancers in women in the U.S., and can take a severe emotional and mental toll on patients and their families. Sun Life's Bright Paper discusses the link between mental health and breast cancer, barriers to access treatment, recommendations, and more.
Kidney related conditions consistently rank within Sun Life's top 10 high-cost claims, and having kidney disease is surprisingly common. Sun Life's Bright Paper addresses kidney disease risk factors, barriers to care, and recommendations for employers to help employees manage their health, while also controlling claim costs.
Arthritis, the leading cause of work disability, affects 1 in 4 adults and has no cure yet. In this article, Sun Life shares insights on the long-term condition, and covers the impacts it can have on employees and employers, high-cost arthritis claims, and research on current and potential drug therapies.
Watch Marjory Robertson, AVP & Senior Counsel, Sun Life and Abigail O’Connell, Senior Counsel, Sun Life, for a recap of 2023 legal and compliance developments related to leave and accommodation law. They also provided updates on the federal Pregnancy Workers Fairness Act, and other compliance issues trending in 2024.
What's top of mind for Sun Life in 2024? Sun Life leaders share insights on the importance of gene therapies, the benefits of receiving care at home, and legislative impacts on healthcare policy in 2024.
Watch as Marjory Robertson, AVP & Senior Counsel, Sun Life U.S. and Abigail O’Connell, Senior Counsel, recap the latest 2023 leave and accommodation-related compliance developments.
They also include a section on recent jury verdicts involving the FMLA and the ADA, which is always an audience favorite.
For the past eleven years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims. While a lot has changed over the eleven years, one thing has not: our commitment to providing you with actionable insights that can help you stay informed about conditions and medications most likely to result in a high-cost claim, and steps you can take to manage that risk as a self-funded employer.
Join our team of experts dive deeper into our key insights and provide actionable recommendations for employers.
What's top of mind for Sun Life leaders? Sun Life's SVP of Health and Risk Solutions, Jennifer Collier and James Slotnick, Head of Government Relations share their perspectives on the evolving industry landscape in this 2023 Future Forecast.
Learn more about recently approved Hemgenix in the treatment of Hemophilia B, the gene therapy pipeline, the approval process, and what gene therapies are, in our second edition of the Introduction to Gene Therapies paper.
